Dendreon (DNDNQ) Stock Price, News & Analysis

Company Overview

Dendreon Corporation is a biotechnology company focused on the development and commercialization of immunotherapy treatments for cancer. Its core business revolves around harnessing the body’s immune system to target and eliminate tumor cells. Dendreon’s technology platform centers on autologous cell therapy, in which a patient’s own immune cells are processed and activated outside the body before being reinfused to stimulate an anti-cancer response.

The company’s flagship product, sipuleucel-T (Provenge), received U.S. Food and Drug Administration approval in 2010 as the first therapeutic cancer vaccine for patients with asymptomatic or minimally symptomatic metastatic castrate-resistant prostate cancer. Provenge is manufactured through a tightly controlled process in which antigen-presenting cells are exposed to a prostate cancer–specific antigen fused with an immune cell activator. Once reinfused, these cells prime the patient’s immune system to recognize and attack prostate tumor cells.

Founded in 1992 and headquartered in Seattle, Washington, Dendreon built commercial-scale manufacturing and distribution capabilities in the United States to support Provenge therapy. The company’s operations have included a centralized production facility in New Jersey and a network of collection sites for leukapheresis across North America. In 2015, Dendreon was acquired by Valeant Pharmaceuticals (now Bausch Health Companies), and Provenge continues to be marketed under that ownership, with Dendreon’s research and development heritage informing ongoing efforts in cancer immunotherapy.

Key Stats

• Today's Range: N/A
• 50-Day Range: N/A
• 52-Week Range: N/A
• Volume: N/A
• Average Volume: N/A
• Market Capitalization: N/A
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: N/A
• Consensus Rating: N/A

DNDNQ Stock Analysis - Frequently Asked Questions

How were Dendreon's earnings last quarter?

Dendreon Corporation (OTCMKTS:DNDNQ) posted its quarterly earnings data on Monday, November, 10th. The biotechnology company reported ($0.14) earnings per share (EPS) for the quarter, missing analysts' consensus estimates of ($0.10) by $0.04. Dendreon's revenue was up 7.5% on a year-over-year basis.

How do I buy shares of Dendreon?

Shares of DNDNQ stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services.

Company Calendar

• Last Earnings: 11/10/2014
• Today: 9/15/2025

Industry, Sector and Symbol

• Stock Exchange: OTCMKTS
• Sector: Manufacturing
• Industry: Pharmaceutical Preparations
• Sub-Industry: Pharmaceutical Products
• Current Symbol: OTCMKTS:DNDNQ
• Previous Symbol: NASDAQ:DNDN
• CIK: N/A
• Web: www.dendreon.com
• Phone: +1-206-2197815
• Fax: N/A
• Employees: N/A
• Year Founded: N/A

Profitability

• EPS (Trailing Twelve Months): N/A
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: N/A
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: N/A
• Return on Assets: N/A

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: N/A
• Quick Ratio: N/A

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: N/A
• Price / Book: N/A

Miscellaneous

• Outstanding Shares: N/A
• Free Float: N/A
• Market Cap: N/A
• Optionable: Not Optionable
• Beta: N/A